ArticleMethods in molecular biology (Clifton, N.J.)2026
Intramuscular and Intravenous AAV-Mediated Gene Delivery in Mouse Models.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinant adeno-associated virus (rAAV)-mediated gene therapy is a powerful approach for precise delivery of desired eukaryotic genes to a wide range of target cells and tissues to treat various types of muscular and neuromuscular diseases, including spinal muscular atrophy, Duchenne/Becker muscular dystrophy (DMD/BMD), and limb-girdle muscular dystrophy.Proof-of-concept, preclinical, and clinical studies in these and other fields have demonstrated high transduction efficiency of naturally occurring and engineered rAAV serotypes across multiple mammalian species, from rodents and dogs to nonhuman primates and humans, to target skeletal muscles, heart, diaphragm, and central nervous system via various routes of administration. Among them, intramuscular and intravenous injections are the most widely used routes for administering therapeutic molecules such as rAAV vector particles in dystrophic animals.The protocols compiled in this chapter describe a simple, reliable, and reproducible method for injecting rAAV vectors using both administration techniques to deliver genes of interest into neonates and adult mice to study muscular and neuromuscular diseases and develop therapeutic options for their treatment.
Indexed as
Identifiers
41028320What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.